A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Walter L. Vervenne, Jaafar Bennouna, Yves Humblet, Stan Gill, Malcolm J. Moore, Jean‐Luc Van Laethem, Aijing Shang, Jan Cosaert, Chris Verslype, Eric Van Cutsem

Journal of Clinical Oncology · 2008 · 50 citations · 0 references

Concepts

Abstract

4507 Background: The phase II B+G trial showed a 21% response rate (RR) with a median overall survival (OS) of 8.8 months [Kindler, JCO 2005]. In the phase III OS trial of G+E vs. G the hazard ratio (HR) was 0.82 (95% CI 0.69–0.99; p=0.0328) [Moore, JCO 2007]. Therefore, a phase III trial exploring GE±B was conducted. Methods: Eligible pts had chemonaive, metastatic pancreatic adenocarcinoma and KPS 60–100. The primary endpoint was OS. The sample size allowed the detection of a 30% improvement in median OS (6.9 vs. 9.0 mo, 80% power). Pts received B/P at 5 mg/kg q2w (IV) added to daily E (100 mg/day PO) and G (1,000 mg/m2 30 min IV) given weekly for 7 weeks during first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles. CT scans were performed every 8 weeks. Results: 607 pts were enrolled (Jul05-Sep06). Pt characteristics (301GE-P/306GE-B): male 62%/57%; median age 61y/62y; KPS <80 13%/13%. Median duration of follow-up: 177/203 days. As of Mar07 454 pts (233/221) had died. Median OS 6.0/7.1 mo (HR 0.89; 95% CI 0.74–1.07). Median PFS 3.6/4.6 mo (HR 0.73; 95% CI 0.61–0.86; p=0.0002). Response: complete response 0%/0.7%; partial response 8.6%/12.8%, progressive disease 24.3%/19.9%. Grade 3–4 AEs: no clinically relevant difference observed (see table). Hypertension (Gr 3): 1%/3%; GI perforation 1%/<1%. All grade AEs: bleeding: 23%/42% (mainly epistaxis, 11%/29%); proteinuria 1%/5%; venous thrombosis 18%/15%. Multiple cox regression analysis was performed on OS adjusting for baseline covariates. Conclusion: Addition of B to GE did not lead to significantly longer OS, but there was a trend towards improved OS (95% CI 0.74–1.07) with significantly improved PFS (p=0.0002) in metastatic pancreatic cancer. GEB was very well tolerated. A further update of the data is planned in early 2008. Grade 3 - 4 AEs GE-P (N-287) GE-B (N-296) Pts % Pts % Neutropenia 50 17 62 21 Anemia 26 9 20 7 Thrombocytopenia 18 6 24 8 Fatigue 19 7 16 5 Rash 9 3 23 8 Diarrhea 16* 6 11 4 *1 pt died Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche